DexCom, Inc. (NASDAQ:DXCM) is one of the Best Fundamental Stocks to Buy According to Analysts. On January 12, the company ...

Dexcom’s new CEO is eyeing growth in the international market as a key strategy for 2026, fresh off the back of the company ...

Wondering whether DexCom's current share price lines up with its underlying worth, or if the market is missing something ...

Fintel reports that on January 12, 2026, Barclays downgraded their outlook for DexCom (NasdaqGS:DXCM) from Equal-Weight to ...

In addition to Canaccord Genuity, Dexcom also received a Buy from TD Cowen’s Josh Jennings in a report issued yesterday. However, on the same day, Barclays reiterated a Sell rating on Dexcom (NASDAQ: ...

Supermodels, singers, and diabetics are all wearing it. Jake Leach, Dexcom CEO, says these sensors are the future.

What Happened? Shares of medical device company DexCom (NASDAQ:DXCM) fell 2.6% in the morning session after analysts at Piper ...

In his inaugural J.P. Morgan Healthcare Conference speech, newly minted Dexcom CEO Jake Leach looked to ease concerns over ...

Bernstein analyst Lee Hambright maintained a Buy rating on Dexcom today and set a price target of $86.00. Claim 70% Off TipRanks Premium. Unlock hedge fund-level data and powerful ...

Investing.com -- Barclays downgraded DexCom and Insulet, two large-cap diabetes device makers, to Underweight as it expects rising competition in 2026 and 2027 to weigh on valuation multiples and ...

Dexcom convinced a federal judge that its phrasing about market share in two statements about sales growth for certain ...

In July, Leach was tapped to take the CEO role permanently at the start of 2026 as part of Dexcom’s planned succession ...